Investigating the role of TIGIT in kidney injury and recovery
Official title: TIGIT in acute kidney injury and repair
Funded at Johns Hopkins University · NIH-11103237 · Data updated 2026-11-12
This study is looking at how a molecule called TIGIT influences the immune response in people with acute kidney injury, especially those receiving cancer treatments, to help find better ways to protect and heal their kidneys.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 10, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $447,939 |
| NIH project number | 5R01DK132278-03 |
| Project ID | NIH-11103237 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients who have experienced acute kidney injury, especially those receiving immune checkpoint inhibitors for cancer treatment.
✕Less likely to help
Patients with chronic kidney disease or those not undergoing cancer treatment may not benefit from this research.
What this research studies
This research focuses on understanding how a specific immune checkpoint molecule, TIGIT, affects the activation of T cells during acute kidney injury (AKI). By studying the immune response in both animal models and human samples, the researchers aim to uncover the mechanisms by which TIGIT contributes to kidney damage and repair. The approach includes advanced techniques like RNA sequencing and flow cytometry to analyze T cell behavior in the context of kidney injury. The ultimate goal is to develop new therapies that could improve outcomes for patients suffering from AKI, particularly those undergoing cancer treatments that may exacerbate kidney issues.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect the kidneys from injury and improve recovery for patients with acute kidney injury.
How similar studies have gone: Previous studies have shown promising results in understanding immune mechanisms in kidney injury, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Noel, Sanjeev — Johns Hopkins University
- Study coordinator: Noel, Sanjeev
Related research
Other NIH-funded projects on the same topics.
-
SEAK Alliance: Improving Care for AKI Patients in the Southeast
A national, patient-centered effort to improve post-hospital care for people who had acute kidney injury in the Southeast.
-
AKI-related delirium after heart surgery
This grant funds research to understand why some people develop delirium after heart surgery when they also have acute kidney injury.
-
Better ways to identify types of sudden kidney injury in U.S. Veterans
Researchers are looking for genetic and health patterns that define different types of sudden severe kidney injury in Veterans to help guide future care.
-
Neuroimmune control of kidney injury using noninvasive ultrasound
A new approach uses targeted ultrasound to gently stimulate nerves and immune signals to help the kidney recover after injury.
-
Structure-based approach to prevent kidney injury from polymyxin use
Aims to block how polymyxin damages the kidney so it can be used more safely to treat hard-to-kill infections.
-
Using smart computer predictions to prevent kidney injury after heart surgery
A machine-learning approach uses routinely collected hospital data to predict who might develop acute kidney injury after heart surgery, so clinicians can act early.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.